ASH 2019 | FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies
Bahram Valamehr, PhD, Fate Therapeutics Inc., San Diego, CA, discusses the multi-antigen targeted CAR-iNK (iPSC derived natural killer) cell immunotherapy for B-cell malignancies as a monotherapy and in combination with monoclonal antibody therapy such as rituximab, FT596. This engineered immune cell is consistently manufactured from a master iPSC line engineered to uniformly express an NK cell-calibrated CD19-targeting CAR, an enhanced functioning high-affinity, non-cleavable CD16 (hnCD16) and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF) for cytokine-autonomous persistence. Studies performed demonstrated FT596 provides a multi-antigen targeting, potent and persistent engineered immune cell. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
